Skip to main content

Dr. Kaitlin A. Ryan, M.D.

Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)

At a glance

Years since graduation
14
In the NPI registry since
2012

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2012Medical school: Temple University School of Medicine
  • 2012Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Advanced Heart Failure and Transplant Cardiology Physician primary
    TN license 57489
  • Pediatric Cardiology Physician
    TN license 57489
  • Student in an Organized Health Care Education/Training Program

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Heart Failure & Transplant Cardiology per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Payments from drug and device companies

In 2025, 4 companies reported 4 payments worth $320 in total to this clinician.

By type
Food and Beverage$320

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Tennessee →

Industry-funded research

Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $30,862 in research payments for these studies, mostly to the institutions running them.

  • A Phase 2,3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants with Heart Failure due to Systemic Left Ventricul…
    Merck Sharp & Dohme LLC
  • A Phase 3, Single-arm, Open-label Extension of the Vericiguat VALOR Study in Pediatric Participants with Heart Failure due to Systemic Left Ventricular Systolic Dysfunction VALOR EXT
    Merck Sharp & Dohme LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Heart Failure & Transplant Cardiology clinicians in Memphis

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 9, 2025), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1598022675. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.